Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2007

CHDI to Leverage ActiveSight’s Fragment-Based Lead Discovery Know-How for Huntington's

  • ActiveSight will collaborate on a fragment-based lead discovery (FBLD) project with CHDI related to Huntington's disease (HD). The companies hope that the FBLD approach will lead to therapies in shorter time periods than conventional methods.

    ActiveSight will screen libraries using x-ray crystallography to visualize fragments that bind to a CHDI-selected HD target. The fragments will then be linked or grown into larger, drug-like compounds. These are thought to be more efficiently binding than compounds resulting from HTS methodologies, according to the firms.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »